Search

Displaying results 8881 - 8890 of 10000 in total
  1. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  2. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...

  3. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. … OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA).

    Synonyms: Combretastatin A-1 bis(phosphate)
  4. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.

  5. Drug

    TH0318

    go.drugbank.com/drugs/DB05145
    Experimental

    TH0318 is a stabilized analogue of human GLP-1 (glucagon-like peptide-1) under investigation for the treatment of type 2 diabetes.

    Synonyms: ThGLP-1
  6. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  7. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.

  8. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  9. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  10. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. … It is currently under investigation by AmpliMed and is in phase I of clinical trial.